{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:08:38Z","timestamp":1792728518729,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.anl.2018.07.011","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T09:33:42Z","timestamp":1534498422000},"page":"196-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media"],"prefix":"10.1016","volume":"46","author":[{"given":"Yukiko","family":"Iino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2018.07.011_bib0005","series-title":"Recent advances in otitis media","first-page":"183","article-title":"Intractable otitis media in cases with bronchial asthma","author":"Tomioka","year":"1993"},{"key":"10.1016\/j.anl.2018.07.011_bib0010","series-title":"Cholesteatoma and mastoid surgery","first-page":"851","article-title":"Intractable otitis media in patients with bronchial asthma (eosinophilic otitis media)","author":"Tomioka","year":"1997"},{"key":"10.1016\/j.anl.2018.07.011_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0385-8146(01)00124-9","article-title":"Clinical characteristics of so-called eosinophilic otitis media","volume":"29","author":"Nagamine","year":"2002","journal-title":"Auris Nasus Larnyx"},{"key":"10.1016\/j.anl.2018.07.011_bib0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.anl.2010.11.016","article-title":"Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease","volume":"38","author":"Iino","year":"2011","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.anl.2018.07.011_bib0025","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/MAO.0b013e318263d5b8","article-title":"Clinical efficacy of anti-IgE therapy for eosinophilic otitis media","volume":"33","author":"Iino","year":"2012","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.anl.2018.07.011_bib0030","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizuzmmab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2018.07.011_bib0035","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2018.07.011_bib0040","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1081-1206(10)60967-2","article-title":"Effectiveness of instillation of triamcinolone acetonide into middle ear for eosinophilic otitis media associated with bronchial asthma","volume":"97","author":"Iino","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anl.2018.07.011_bib0045","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.anl.2018.07.011_bib0050","unstructured":"Global Initiative for Asthma (GINA) Blobal strategy for asthma management and prevention. http:\/\/ginasthma.org\/wp-content\/uploads\/2018\/04\/wms-GINA-2018-report-tracked_v1.3.pdf. 2018."},{"key":"10.1016\/j.anl.2018.07.011_bib0055","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2018.07.011_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severs nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2018.07.011_bib0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/0036554021000028117","article-title":"IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion","volume":"123","author":"Nonaka","year":"2003","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2018.07.011_bib0070","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1365-2222.2005.02330.x","article-title":"Eosinophil chemoattractant in middle ear of patients with eosinophilic otitis media","volume":"35","author":"Iino","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anl.2018.07.011_bib0075","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(08)61452-X","article-title":"Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease","volume":"372","author":"Anderson","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.anl.2018.07.011_bib0080","first-page":"513","article-title":"The role of periostin in eosinophilic otitis media","volume":"41","author":"Kanazawa","year":"2014","journal-title":"Acta Otolarngol"},{"key":"10.1016\/j.anl.2018.07.011_bib0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2332\/allergolint.13-RAI-0673","article-title":"Expressions and roles of periostin in otolaryngological diseases","volume":"63","author":"Ohta","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2018.07.011_bib0090","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/MAO.0b013e318185fb0d","article-title":"Bone conduction hearing level in patients with eosinophilic otitis media associated with bronchial asthma","volume":"29","author":"Iino","year":"2008","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.anl.2018.07.011_bib0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MAO.0b013e3181bc3781","article-title":"Eosinophilic inflammation in the middle ear induces deterioration of bone conduction hearing level in patients with eosinophilic otitis media","volume":"31","author":"Iino","year":"2010","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.anl.2018.07.011_bib0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/00016489.2013.859395","article-title":"An experimental study of inner ear injury in an animal model of eosinophilic otitis media","volume":"134","author":"Matsubara","year":"2014","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2018.07.011_bib0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.anl.2018.07.011_bib0110","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1513\/AnnalsATS.201303-047AW","article-title":"Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma","volume":"10 Suppl","author":"Arron","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.anl.2018.07.011_bib0115","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2018.07.011_bib0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814618304322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814618304322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:34:40Z","timestamp":1759952080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814618304322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0385814618304322"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2018.07.011","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2018.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}